An official website of the United States government
Program Director
Clinical and Translational Epidemiology Branch, Epidemiology and Genomics Research Program
Telephone: (240) 276-6897
E-mail: nshelburne@mail.nih.gov
- MS - Advanced Practice Oncology Nursing, University of Maryland at Baltimore School of Nursing
- BS - Nursing, University of Maryland at Baltimore School of Nursing
- Cancer survivorship
- Cancer genetic counseling, testing, and follow-up care
- Risk prediction and risk stratification models
- Dissemination and implementation
Biography
Ms. Nonniekaye Shelburne is a program director in the Epidemiology and Genomics Research Program's (EGRP) Clinical and Translational Epidemiology Branch (CTEB). Her research portfolio focuses on improving outcomes for cancer survivors through risk identification and mitigation and management strategies for early and late-onset adverse events related to cancer and cancer treatment.
Ms. Shelburne oversees multiple Programmatic research initiatives across cancer survivorship, with special focus on:
- Cancer Treatment-related Cardiotoxicity
- Oncologic Emergencies and the Comprehensive Oncologic Emergencies Research Network (CONCERN)
- Blood and Marrow Transplantation Late Effects
- Cancer Moonshot: Inherited Cancer Syndromes
- Adolescent and Young Adult Cancer Survivorship
Before joining EGRP in 2010, Ms. Shelburne worked as an acute care nurse practitioner and oncology clinical nurse specialist with the Hematology/Oncology/Stem Cell Transplant Program of Care at the NIH Clinical Center. From 1998-2004, she was a clinical research nurse within the same program. Her focus was on improving the clinical and research outcomes of patients in phase I and II clinical trials for cancer and hematological disorders. Ms. Shelburne was an associate investigator on cancer patient and caregiver stress, problem solving interventions, and quality of life trials from 2003-2018. Ms. Shelburne’s other interests included development of risk predication tools for patient falls and acute delirium.
Select Publications
Williams CP, Senft Everson N, Shelburne N, Norton WE. Demographic and Health Behavior Factors Associated with Clinical Trial Invitation and Participation in the United States. JAMA Netw Open. 2021 Sept 1;4(9):e2127792.
Shelburne N, Simonds NI, Adhikari B, Alley M, Desvigne-Nickens P, Dimond E, Filipski K, Gallicchio L, Minasian L. Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity. Curr Oncol Rep. 2019 Jan 30;21(1):9.
Rivera D, Gallicchio L, Brown J, Liu B, Kyriacou JN, Shelburne N. Trends in Adult Cancer-related Emergency Department Utilization: An analysis of data from the Nationwide Emergency Department Sample. JAMA Oncol. 2017 Oct 12;3(10):e172450.
Shaw BE, Hahn T, Martin PJ, Mitchell S, Peterdorf EW, Armstrong GT, Shelburne N, Storer B, Bhatia S. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Research Methodology and Study Design Working Group Report. Biol Blood Marrow Transplant. 2017 Jan;23(1);10-23.
Brown J, Grudzen C, Kyriacou J, Obermeyer Z, Quest T, Rivera D, Stone S, Wright J, Shelburne N. The Emergency Care of Patients With Cancer: Setting the Research Agenda. Ann Emerg Med. 2016 Dec;68(6):706-711.
Shelburne N, Adhikari B, Brell J, Davis M, Desvigne-Nickens P, Freedman A, Minasian L, Foce T, Remick SC. Cancer treatment-related cardiotoxicity: current state of knowledge and research priorities. J Natl Cancer Inst. 2014 September 10;106(9).
Battiwalla M, Hashmi S, Majhail N, Pavletic S, Savani BN, Shelburne N. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. Biol Blood Marrow Transplant. 2017 Jan;23(1):6-9.